Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes. The co-primary endpoints w...

Descripción completa

Detalles Bibliográficos
Autores principales: Garvey, W. Timothy, Batterham, Rachel L., Bhatta, Meena, Buscemi, Silvio, Christensen, Louise N., Frias, Juan P., Jódar, Esteban, Kandler, Kristian, Rigas, Georgia, Wadden, Thomas A., Wharton, Sean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556320/
https://www.ncbi.nlm.nih.gov/pubmed/36216945
http://dx.doi.org/10.1038/s41591-022-02026-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556320/
https://www.ncbi.nlm.nih.gov/pubmed/36216945
http://dx.doi.org/10.1038/s41591-022-02026-4

Ejemplares similares